DOI:https://doi.org/10.1016/S2213-2600(20)30316-7
The Lancet Respiratory Medicine
Glob Heart . 2020 Oct 13;15(1):69. doi: 10.5334/gh.891.
While the COVID-19 pandemic threatens all members of society, persons with disabilities are disproportionately impacted due to attitudinal, environmental and institutional barriers that are reproduced in the COVID-19 response.
19 April 2020
To contain the spread of COVID-19 and to keep infections at a manageable level, many countries have instituted lockdowns and social distancing. In India, a nationwide 21-day lockdown was announced with effect from 25 March 2020. This lockdown is expected to avert a sudden and large in...crease in the number of infections in the short term. Additionally, interventions such as social distancing and isolation of infected individuals over several months could reduce peak infections. Interventions such as frequent handwashing, reduced mass gatherings, contact tracing, and quarantines could slow transmission and reduce overall infections.
more
Journal of Social Work in Developing Societies 13
Vol. 2(1): 13-25 , June 2020
Alternative Thematic Report on implementation of the Convention on Elimination of all Forms of discrimination against Women on the issues related to women living with HIV from the affected groups (women – former prisoners, women using injected drugs, women sex workers).
Accessed: 04.10.2019
Southern African Journal of HIV Medicine
ISSN: (Online) 2078-6751, (Print) 1608-9693
http://www.sajhivmed.org.za
Published: 23 May 2018
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 23, No. 11, November 2017
In case of resistance to rifampicin, fluoroquinolones become the preferred category of second-line drugs. Unfortunately, quinolone-resistant strains of Mycobacterium leprae have also been reported in several countries, probably due to the extensive use of quinolones for treating several types of inf...ections. Clofazimine resistance is still rare but this antimicrobial cannot be given alone
more
The growing challenges for people in low and middle-income countries to access new medicines.
Analysis 58
The Lancet Published Online September 13, 2016 http://dx.doi.org/10.1016/S0140-6736(16)31404-0